Cognition Therapeutics, Inc.
- CGTX
- NASDAQ
- Biotechnology
- Neurodegenerative (CNS) Drugs
- Clinical-Stage Biopharma
$0.73
Today −0.33%Quote Oct 19, 2026, 08:00 PM UTC
−30.06%over the last month
Max drawdown −30.1%From 1-month high −30.1%3 months −27.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Cognition Therapeutics
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
14
Market value
$69.2M
Quote Oct 19
Analyst target
$3.00
+312.4% from here
Floor
$0.65
10.4% below price
Resistance
$0.79
8.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CGTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free